ANPI Angiotech Pharmaceuticals - Common Shares (MM)

Angiotech corporate partner announces court decision denying preliminary injunctions on drug eluting stents VANCOUVER, Nov. 21 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. , the original developer of the paclitaxel-coated stent technology, today was notified by its corporate partner, Boston Scientific Corporation, that the that the U.S. District Court in Wilmington, Delaware has denied a motion by Cordis Corporation seeking a preliminary injunction against Boston Scientific's TAXUS(TM) drug-eluting stent system and has denied a motion by Boston Scientific seeking a preliminary injunction against Cordis' CYPHER(TM) drug-eluting stent system. The motions had been brought in lawsuits in which each of the companies has alleged patent infringement against the other. Both patent infringement cases remain pending. Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. Angiotech Pharmaceuticals, Inc. is dedicated to enhancing the performance of medical devices and biomaterials through the innovative use of pharmacotherapeutics. To find out more about Angiotech Pharmaceuticals, Inc (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), visit our website at http://www.angiotech.com/. Angiotech Pharmaceuticals Contact: Ian Harper (investors & media) ext. 6933 Rui Avelar (analysts) ext. 6996 Phone: (604) 221-7676 Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continue," "estimate," "expects," "may" and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with the United States Securities and Exchange Commission or the Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements. DATASOURCE: Angiotech Pharmaceuticals, Inc. CONTACT: Angiotech Pharmaceuticals Contact: Ian Harper (investors & media) ext. 6933, Rui Avelar (analysts) ext. 6996, Phone: 604-221-7676

Copyright